Guselkumab shows significant clinical and endoscopic benefits for adults with moderate to severe Crohn disease, offering a ...

Common unpleasant symptoms after eating too much of the wrong thing happen to just about anyone. Cramping, nausea, abdominal pain or gas typically don't last long, but if you have Crohn's ...

2024 — A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy to all patients straight after diagnosis can drastically improve ...

A research team at Mount Sinai have developed a risk score they found accurate in predicting Crohn’s disease in patients ...

Marking World IBD Day, a pediatric gastroenterologist discusses symptoms, treatment options, and the ongoing search for a ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved guselkumab (Tremfya) for the treatment of Crohn’s ...

It can cause a wide range of symptoms, from abdominal pain to arthritis. Symptoms tend to follow a relapsing-remitting ...

Crohn’s Disease Market to grow from $11.82B in 2023 To $17.15B by 2031, at a 4.8% CAGR, driven by rising IBD prevalence and ...

The U.K.’s Medicines and Healthcare products Regulatory Agency has approved guselkumab, or Tremfya, to treat Crohn’s disease ...

Older patients with Crohn’s disease are at elevated risk for recurrence following ileocolic resection but less frequently ...

In India, Inflammatory Bowel Disease is on the rise, requiring increased awareness, timely intervention, and holistic care ...